Risk prediction in the management of small renal masses

Current Opinion in Urology

Volumn 22, Issue 5, 2012, Pages 347-352

  Bagrodia, Aditya ^a   Darwish, Oussama M ^a   Rapoport, Yury ^a   Margulis, Vitaly ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOVENOUS FISTULA; CANCER MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST RADIOGRAPHY; DIAGNOSTIC ACCURACY; HEMATOMA; HUMAN; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY MASS; MEDICAL DECISION MAKING; NEPHRECTOMY; ONCOCYTOMA; PARTIAL NEPHRECTOMY; PERCUTANEOUS BIOPSY; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMOTHORAX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; TUMOR SEEDING;

BIOPSY; DISEASE MANAGEMENT; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY NEOPLASMS; NEPHRECTOMY; PROGNOSIS; RISK FACTORS;

EID: 84864860753     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328355ede9     Document Type: Review

References (49)

1. Gill IS, Aron M, Gervais DA, et al. Clinical practice: small renal mass. N Engl J Med 2010; 362:624-634.
2. Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738-745. (Pubitemid 38176851)
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490. (Pubitemid 41770167)
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
5. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51:203-205. (Pubitemid 28093168)
6. Joly D, Mejean A, Correas JM, et al. Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease. J Urol 2011; 185:2056-2060.
7. Matin SF, Ahrar K, Wood CG, et al. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int 2008; 102:940-945.
8. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7cm or less amenable to partial nephrectomy. J Urol 2007; 178:429-434. (Pubitemid 47030487)
9. Eggener SE, Rubenstein JN, Smith ND, et al. Renal tumors in young adults. J Urol 2004; 171:106-111.
10. Kates M, Korets R, Sadeghi N, et al., Predictors of locally advanced and metastatic disease in patients with small renal masses. BJU Int 2011; 109:1463-1467.
11. Abel EJ, Culp SH, Meissner M, et al. Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int 2010; 106:1277-1283.
12. Jeldres C, Sun M, Liberman D, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol 2009; 182:2585-2589.
13. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007; 109:1763-1768. (Pubitemid 46668538)
14. Kutikov A, Egleston BL, Wong YN, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28:311-317.
15. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 2008; 179:857-861. (Pubitemid 351208417)
16. Sengupta S, Lohse CM, Cheville JC, et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 2006; 106:304-312. (Pubitemid 43100438)
17. Magera JS Jr, Leibovich BC, Lohse CM, et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008; 71:278-282. (Pubitemid 351282342)
18. Kawai Y, Matsuyama H, Korenaga Y, et al. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol Int 2009; 83:306-310.
19. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6:149-163.
20. Wu Y, Fu X, Zhu X, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2011; 137:887-896.
21. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170:2217-2220. (Pubitemid 37413960)
22. Russo P. Should elective partial nephrectomy be performed for renal cell carcinoma >4 cm in size? Nat Clin Pract Urol 2008; 5:482-483.
23. Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 2009; 181:2033-2036.
24. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol 2009; 181:1020-1027; discussion 1027.
25. Sun MR, Ngo L, Genega EM, et al. Renal cell carcinoma: dynamic contrastenhanced MR imaging for differentiation of tumor subtypes - correlation with pathologic findings. Radiology 2009; 250:793-802.
26. Alshumrani G, O'Malley M, Ghai S, et al. Small (< or =4 cm) cortical renal tumors: characterization with multidetector CT. Abdom Imaging 2010; 35:488-493.
27. Millet I, Doyon FC, Hoa D, et al. Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT? AJR Am J Roentgenol 2011; 197:887-896.
28. Birnbaum BA, Bosniak MA, Krinsky GA, et al. Renal cell carcinoma: correlation of CT findings with nuclear morphologic grading in 100 tumors. Abdom Imaging 1994; 19:262-266. (Pubitemid 24126431)
29. Zhang J, Lefkowitz RA, Ishill NM, et al. Solid renal cortical tumors: differentiation with CT. Radiology 2007; 244:494-504. (Pubitemid 47080882)
30. Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 2011; 60:241-248.
31. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 2007; 8:304-310. (Pubitemid 46464522)
32. Pedrosa I, Rafatzand K, Robson P, et al. Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol 2012; 22:484-492.
33. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol 1995; 13:254-261.
34. Lebret T, Poulain JE, Molinie V, et al. Percutaneous core biopsy for renal masses: indications, accuracy and results. J Urol 2007; 178:1184-1188; discussion 1188. (Pubitemid 47368414)
35. Volpe A, Mattar K, Finelli A, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol 2008; 180:2333-2337.
36. Maturen KE, Nghiem HV, Caoili EM, et al. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol 2007; 188:563-570. (Pubitemid 46167760)
37. Wang R, Wolf JS Jr, Wood DP Jr, et al. Accuracy of percutaneous core biopsy in management of small renal masses. Urology 2009; 73:586-590; discussion 590-591.
38. Veltri A, Garetto I, Tosetti I, et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 2011; 21:393-401.
39. Nishikimi T, Tsuzuki T, Fujita T, et al. The postoperative pathological prognostic parameters of clear cell renal cell carcinoma in pT1a cases. Pathol Int 2011; 61:116-121.
40. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26:281-291. (Pubitemid 34184451)
41. Dall'Oglio MF, Antunes AA, Sarkis AS, et al. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 2007; 100:552-555. (Pubitemid 47205472)
42. Lang H, Lindner V, Letourneux H, et al. Prognostic value of microscopic venous invasion in renal cell carcinoma: long-term follow-up. Eur Urol 2004; 46:331-335. (Pubitemid 39078566)
43. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58:398-406.
44. Waldert M, Haitel A, Marberger M, et al. Comparison of type I andIIpapillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int 2008; 102:1381-1384.
45. Kawaciuk I, Hyrsl L, Dusek P, et al. Influence of tumour-associated symptoms on the prognosis of patients with renal cell carcinoma. Scand J Urol Nephrol 2008; 42:406-411.
46. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009; 115:2844-2852.
47. Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007; 38:1489-1495. (Pubitemid 47418959)
48. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107:1793-1800. (Pubitemid 44582948)
49. Kaya K, Ayan S, Gokce G, et al. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol 2005; 39:25-29. (Pubitemid 40380439)